Click here to read the full article, wherein the success of Zymeworks founder Ali Tehrani, and the strategies of the company are explored in detail.

Zymeworks Inc. has risen quickly to the forefront of the Canadian pharmaceuticals industry, propelled by venture capital financing of USD$61.5 million in January 2016, and a subsequent partnership with GlaxoSmithKline to develop at least four drug candidates that could yield milestone payments of US$110 million, per drug.

Brian Bloom, president of Bloom Burton and Co recently commented upon the success of Zymeworks, to Canadian Business,  that, “There are two ways to receive validation: from partnerships with big pharma and from smart investors. Zymeworks has both.”